Stock Analysis

Fenix Outdoor International Full Year 2024 Earnings: EPS: €0.42 (vs €2.37 in FY 2023)

OM:FOI B
Source: Shutterstock

Fenix Outdoor International (STO:FOI B) Full Year 2024 Results

Key Financial Results

  • Revenue: €698.8m (down 5.5% from FY 2023).
  • Net income: €14.6m (down 54% from FY 2023).
  • Profit margin: 2.1% (down from 4.3% in FY 2023). The decrease in margin was driven by lower revenue.
  • EPS: €0.42 (down from €2.37 in FY 2023).
earnings-and-revenue-history
OM:FOI B Earnings and Revenue History February 13th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Fenix Outdoor International shares are down 1.5% from a week ago.

Risk Analysis

You should learn about the 3 warning signs we've spotted with Fenix Outdoor International (including 1 which is a bit unpleasant).

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About OM:FOI B

Fenix Outdoor International

Develops, manufactures, and sells outdoor products worldwide.

Excellent balance sheet second-rate dividend payer.

Community Narratives

AstraZeneca's Oncology and Obesity Innovations Will Drive Revenue Growth by 10%
Fair Value SEK 2.55k|37.11% undervalued
Unike
Unike
Community Contributor
Leading the Charge in SME SaaS Innovation
Fair Value SEK 100.02|23.535% undervalued
Investingwilly
Investingwilly
Community Contributor
Brookfield Corporation is a solid BUY for a long-term portfolio
Fair Value CA$82.23|1.7389999999999999% overvalued
Jonataninho
Jonataninho
Community Contributor